Trial · NCT02497612
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
NCT02497612, Phase 2, Terminated, Sanofi; results first posted 2020-10-19
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria. Trials, record NCT02497612. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02497612
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
- NCT number
- NCT02497612
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 377 participants, actual
- Lead sponsor
- Sanofi
- Conditions
- Plasmodium Falciparum Infection
- Interventions
- Ferroquine SSR97193, Artefenomel, Placebo
- First posted
- 2015-07-14
- Last updated
- 2022-03-24
- Results first posted
- 2020-10-19
- Limitations and caveats
The study was terminated early because all treatment arms met the futility criteria for efficacy during the pre-planned interim analysis. On 02-August-2018, recruitment in Asia was stopped due to lack of efficacy.
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28) | Day 28 | ACPR: negative parasitemia at Day 28, irrespective of axillary temperature(AT), in participants not meeting any criteria of early therapy failure (ETF):Danger signs (DS)/severe malaria (SM) at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \>Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5 degree Celsius (°C); or parasite count on Day 3\>=25 percent (%) on Day 0, or late clinical failure(LCF):DS/ SM in presence of parasitemia between Day 4 and 28; or presence of parasitemia and AT\>=37.5°C between Day 4 and 28, or late parasitological failure (LPF):presence of parasitemia between Day 7 and 28 and AT\<37.5°C or having rescue therapy for malaria. PCR-adjusted ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with genotype identical to that present at Baseline), excluding participants with re-infection. In data table, "overall number of participants analyzed"=participants evaluable for this outcome measure. |
| Secondary | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: African >5 Years Per Protocol Population at Day 28 (A5PP28) | Day 28 | ACPR: negative parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \> Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5°C; or parasite count on Day 3 \>=25% on Day 0, or LCF: DS/ SM in presence of parasitemia between Day 4 and 28; or presence of parasitemia and AT \>=37.5°C between Day 4 and 28, or LPF: presence of parasitemia between Day 7 and 28 and AT \<37.5°C or having rescue therapy for malaria. PCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection. Here, in the data table, "overall number of participants analyzed"=participants evaluable for this outcome measure. |
| Secondary | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: Asian PP Population at Day 28 (APP28) | Day 28 | ACPR: negative parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \> Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5°C; or parasite count on Day 3 \>=25% on Day 0, or LCF: DS/ SM in presence of parasitemia between Day 4 and 28; or presence of parasitemia and AT \>=37.5°C between Day 4 and 28, or LPF: presence of parasitemia between Day 7 and 28 and AT \<37.5°C or having rescue therapy for malaria. PCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection. Here, in the data table, "overall number of participants analyzed"=participants evaluable for this outcome measure. |
| Secondary | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 42: African <=5 Years PP Population at Day 42 (PP42) | Day 42 | ACPR: negative parasitemia at Day 42, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \> Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5°C; or parasite count on Day 3 \>=25% on Day 0, or LCF: DS/ SM in presence of parasitemia between Day 4 and 42; or presence of parasitemia and AT \>=37.5°C between Day 4 and 42, or LPF: presence of parasitemia between Day 7 and 42 and AT \<37.5°C or having rescue therapy for malaria. PCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection. Here, in the data table, "overall number of participants analyzed"=participants evaluable for this outcome measure. |
| Secondary | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 63: African <=5 Years PP Population at Day 63 (PP63) | Day 63 | ACPR: negative parasitemia at Day 63, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \> Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5°C; or parasite count on Day 3 \>=25% on Day 0, or LCF: DS/ SM in presence of parasitemia between Day 4 and 63; or presence of parasitemia and AT \>=37.5°C between Day 4 and 63, or LPF: presence of parasitemia between Day 7 and 63 and AT \<37.5°C or having rescue therapy for malaria. PCR-adjusted ACPR was applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection. Here, in the data table, "overall number of participants analyzed"=participants evaluable for this outcome measure. |
| Secondary | Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 28: African <=5 Years PP28 Population | Day 28 | ACPR was defined as negative parasitemia at Day 28, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \> Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5°C; or parasite count on Day 3 \>=25% on Day 0, or LCF: DS/ SM in presence of parasitemia between Day 4 and 28; or presence of parasitemia and AT \>=37.5°C between Day 4 and 28 or, LPF: presence of parasitemia between Day 7 and 28 and AT \<37.5°C or having rescue therapy for malaria. PCR-adjusted ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection, whereas crude ACPR does not distinguish re-infection (new clone of parasite) or recrudescence. |
| Secondary | Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 42: African <=5 Years PP42 Population | Day 42 | ACPR was defined as negative parasitemia at Day 42, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \> Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5°C; or parasite count on Day 3 \>=25% on Day 0, or LCF: DS/ SM in presence of parasitemia between Day 4 and 42; or presence of parasitemia and AT \>=37.5°C between Day 4 and 42 or, LPF: presence of parasitemia between Day 7 and 42 and AT \<37.5°C or having rescue therapy for malaria PCR-adjusted ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection, whereas crude ACPR did not distinguish re-infection (new clone of parasite) or recrudescence. |
| Secondary | Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 63: African <=5 Years PP63 Population | Day 63 | Crude ACPR was defined as negative parasitemia at Day 63, irrespective of AT, in participants not meeting any criteria of ETF: DS or SM at Day 1, 2 or 3 in presence of parasitemia; or Day 2 parasite count \> Day 0 irrespective of AT; or parasitemia at Day 3 with AT \>=37.5°C; or parasite count on Day 3 \>=25% on Day 0, or LCF: DS/ SM in presence of parasitemia between Day 4 and 63; or presence of parasitemia and AT \>=37.5°C between Day 4 and 63 or, LPF: presence of parasitemia between Day 7 and 63 and AT \<37.5°C or having rescue therapy for malaria. PCR-adjusted ACPR applied to recrudescence (appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline), excluding participants with re-infection, whereas crude ACPR did not distinguish re-infection (new clone of parasite) or recrudescence. |
| Secondary | Time to Re-emergence | Up to Day 63 | Time to re-emergence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection irrespective of genotype. Participants with no event were censored at the time of study completion, premature study discontinuation, including switch to established anti-malarial treatment or start of any other treatment with anti-malarial activity, whichever was earliest. Re-emergence was confirmed by microscopy (positive blood smear). Kaplan-Maier method was used for estimation. Here, "overall number of participants analyzed"=participants who were included in the analysis of below reported results which consisted of both, who had the event, plus those who were censored. |
| Secondary | Time to Recrudescence | Up to Day 63 | Time to recrudescence (in days) was defined as the time to appearance of asexual parasites after clearance of initial infection with a genotype identical to that of parasites present at Baseline. Recrudescence was confirmed by PCR analysis. Kaplan-Maier method was used for estimation. |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes30
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28) | Day 28 | African \<=5 years PP28: participants with parasitologically confirmed Plasmodium falciparum malaria at screening/baseline, received the single administration of OZ439/FQ, without major protocol violations impacting efficacy, evaluable for crude ACPR at Day 28, excluding those who received rescue treatment due to vomiting during drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: African >5 Years Per Protocol Population at Day 28 (A5PP28) | Day 28 | African \>5 years PP28: participants with parasitologically confirmed Plasmodium falciparum malaria at screening/baseline, received the single administration of OZ439/FQ, without major protocol violations impacting efficacy, evaluable for crude ACPR at Day 28, excluding those who received rescue treatment due to vomiting during drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: Asian PP Population at Day 28 (APP28) | Day 28 | Asian PP28 population: participants with parasitologically confirmed Plasmodium falciparum malaria at screening/baseline, received the single administration of OZ439/FQ, without major protocol violations impacting efficacy, evaluable for crude ACPR at Day 28, excluding those who received rescue treatment due to vomiting during drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 42: African <=5 Years PP Population at Day 42 (PP42) | Day 42 | African \<=5 years PP42: participants with parasitologically confirmed Plasmodium falciparum malaria at screening/baseline, received the single administration of OZ439/FQ, without major protocol violations impacting efficacy, evaluable for crude ACPR at Day 42, excluding those who received rescue treatment due to vomiting during drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 63: African <=5 Years PP Population at Day 63 (PP63) | Day 63 | African \<=5 years PP63: participants with parasitologically confirmed Plasmodium falciparum malaria at screening/baseline, received the single administration of OZ439/FQ, without major protocol violations impacting efficacy, evaluable for crude ACPR at Day 63, excluding those who received rescue treatment due to vomiting during drug administration. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 28: African <=5 Years PP28 Population | Day 28 | Analysis was performed on African \<=5 years PP28 population. Here, overall number of participants analyzed=participants evaluable for this outcome measure. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 42: African <=5 Years PP42 Population | Day 42 | Analysis was performed on African \<=5 years PP42 population. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Crude Adequate Clinical and Parasitological Response at Day 63: African <=5 Years PP63 Population | Day 63 | Analysis was performed on African \<=5 years PP63 population. | percentage of participants | NUMBER |
| SECONDARY | Time to Re-emergence | Up to Day 63 | African \<=5 years modified Intent-To-Treat (mITT) population: all randomized African participants \<=5 years with parasitological confirmed Plasmodium falciparum (P. falciparum) malaria at baseline, who received the single administration of OZ439/FQ and excluding participants who required rescue treatment due to vomiting during drug administration. | days | MEDIAN |
| SECONDARY | Time to Recrudescence | Up to Day 63 | Analysis was performed on African \<=5 years mITT population. Here, overall number of participants analyzed=participants who were included in the analysis of below reported results which consisted of both, who had the event, plus those who were censored. | days | MEDIAN |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 outcomesResults by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28) | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 78.4 | 95% Confidence Interval 64.7 to 88.7 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28) | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 85.0 | 95% Confidence Interval 73.4 to 92.9 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28) | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 89.5 | 95% Confidence Interval 78.5 to 96.0 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28) | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 91.7 | 95% Confidence Interval 81.6 to 97.2 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: African >5 Years Per Protocol Population at Day 28 (A5PP28) | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 72.7 | 95% Confidence Interval 39.0 to 94.0 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: African >5 Years Per Protocol Population at Day 28 (A5PP28) | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 100 | 95% Confidence Interval 69.2 to 100 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: African >5 Years Per Protocol Population at Day 28 (A5PP28) | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 100 | 95% Confidence Interval 73.5 to 100 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: African >5 Years Per Protocol Population at Day 28 (A5PP28) | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 90.0 | 95% Confidence Interval 55.5 to 99.7 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: Asian PP Population at Day 28 (APP28) | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 25.0 | 95% Confidence Interval 0.6 to 80.6 | percentage of participants | |
| Percentage of Participants With Polymerase Chain Reaction-adjusted Adequate Clinical and Parasitological Response at Day 28: Asian PP Population at Day 28 (APP28) | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 25.0 | 95% Confidence Interval 0.6 to 80.6 | percentage of participants |
1 to 10 of 126Source ClinicalTrials.gov
See all 126 results by groupParticipant flow32
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 93 | |
| Overall Study | STARTED | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 94 | |
| Overall Study | STARTED | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 97 | |
| Overall Study | STARTED | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 93 | |
| Overall Study | Treated | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 92 | |
| Overall Study | Treated | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 94 | |
| Overall Study | Treated | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 96 | |
| Overall Study | Treated | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 91 | |
| Overall Study | Cohort 1: >14 Years to <70 Years | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 14 | |
| Overall Study | Cohort 1: >14 Years to <70 Years | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 15 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 participant flowAdverse events72
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Malaria | Infections and infestations | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 55 | 92 | 75 |
| other | Malaria | Infections and infestations | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 50 | 94 | 65 |
| other | Malaria | Infections and infestations | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 40 | 96 | 49 |
| other | Malaria | Infections and infestations | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 41 | 91 | 45 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 7 | 92 | 9 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 6 | 94 | 8 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 17 | 96 | 18 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 10 | 91 | 10 |
| other | Bronchitis | Infections and infestations | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 3 | 92 | 3 |
| other | Bronchitis | Infections and infestations | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 5 | 94 | 5 |
1 to 10 of 72Source ClinicalTrials.gov
See all 72 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 0 | 92 |
| Total, all-cause mortality | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 0 | 94 |
| Total, all-cause mortality | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 0 | 96 |
| Total, all-cause mortality | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 0 | 91 |
| Total, other adverse events | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 77 | 92 |
| Total, other adverse events | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 79 | 94 |
| Total, other adverse events | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 77 | 96 |
| Total, other adverse events | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 74 | 91 |
| Total, serious adverse events | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 0 | 92 |
| Total, serious adverse events | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 2 | 94 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34011358 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02497612
GET https://conductscience.org/api/trials/v1/NCT02497612/registered?page=2